30 Ağustos 2021 Dergi makalesi Açık Erişim

Ebru; Salih; Tuğba; Ömer Faruk; Öznur Özge; Tuğçe; Mesut; Muhsin

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="p">Turkish Journal of Biology</subfield>
    <subfield code="v">45</subfield>
    <subfield code="n">SI-1</subfield>
    <subfield code="c">342-357</subfield>
  </datafield>
  <controlfield tag="001">227979</controlfield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory&amp;nbsp;syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory&amp;nbsp;tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been&amp;nbsp;developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants&amp;nbsp;of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B&amp;nbsp;1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological&amp;nbsp;manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent&amp;nbsp;plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory&amp;nbsp;tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines&amp;nbsp;that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its&amp;nbsp;correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs,&amp;nbsp;and action against emerging viral mutant variants is needed.&lt;/p&gt;</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="2">opendefinition.org</subfield>
    <subfield code="a">cc-by</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="0">(orcid)0000-0003-3838-5228</subfield>
    <subfield code="u">TUNCAY</subfield>
    <subfield code="a">Salih</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="0">(orcid)0000-0002-5885-0193</subfield>
    <subfield code="u">KAMAN</subfield>
    <subfield code="a">Tuğba</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="0">(orcid)0000-0001-7803-3249</subfield>
    <subfield code="u">KARASAKAL</subfield>
    <subfield code="a">Ömer Faruk</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="0">(orcid)0000-0001-8992-0556</subfield>
    <subfield code="u">ÖZCAN</subfield>
    <subfield code="a">Öznur Özge</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="0">(orcid)0000-0002-4663-897X</subfield>
    <subfield code="u">SOYLAMIŞ</subfield>
    <subfield code="a">Tuğçe</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="0">(orcid)0000-0002-8971-678X</subfield>
    <subfield code="u">KARAHAN</subfield>
    <subfield code="a">Mesut</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="0">(orcid)0000-0002-6651-718X</subfield>
    <subfield code="u">KONUK</subfield>
    <subfield code="a">Muhsin</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="b">article</subfield>
    <subfield code="a">publication</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="0">(orcid)0000-0002-0395-9845</subfield>
    <subfield code="u">ÖZKAN OKTAY</subfield>
    <subfield code="a">Ebru</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">COVID-19</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">variants</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">neurological symptoms</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">drugs</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">vaccines</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">neutralizing antibodies</subfield>
  </datafield>
  <datafield tag="653" ind1=" " ind2=" ">
    <subfield code="a">SARS-CoV-2</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2021-08-30</subfield>
  </datafield>
  <controlfield tag="005">20210913065840.0</controlfield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="o">oai:zenodo.org:227979</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="z">md5:8e5500cb80c34102ea79478d4c123d32</subfield>
    <subfield code="s">4383992</subfield>
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/227979/files/biy-45-si-1-1-2106-23.pdf</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by-sa</subfield>
    <subfield code="a">Creative Commons Attribution Share-Alike</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.3906/biy-2106-23</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
</record>